427 related articles for article (PubMed ID: 25687863)
1. Detecting Metastatic Bladder Cancer Using (18)F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography.
Öztürk H
Cancer Res Treat; 2015 Oct; 47(4):834-43. PubMed ID: 25687863
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging renal cell carcinoma.
Ozturk H
Minerva Urol Nefrol; 2016 Jun; 68(3):263-9. PubMed ID: 25916217
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of
Öztürk H; Karapolat I
Exp Ther Med; 2015 Mar; 9(3):717-724. PubMed ID: 25667618
[TBL] [Abstract][Full Text] [Related]
4. Is [F-18]-fluorodeoxyglucose FDG-PET/CT better than ct alone for the preoperative lymph node staging of muscle invasive bladder cancer?
Uttam M; Pravin N; Anish B; Nandita K; Arup M
Int Braz J Urol; 2016; 42(2):234-41. PubMed ID: 27256176
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
6. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
8. Role of
Ozturk H
Rep Pract Oncol Radiother; 2023; 28(6):728-736. PubMed ID: 38515818
[TBL] [Abstract][Full Text] [Related]
9. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
10. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
11.
Öztürk H; Karapolat I
Oncol Lett; 2016 Jan; 11(1):316-322. PubMed ID: 26870210
[TBL] [Abstract][Full Text] [Related]
12. Delayed
Yan H; Zhou X; Wang X; Li R; Shi Y; Xia Q; Wan L; Huang G; Liu J
Radiology; 2019 Oct; 293(1):144-150. PubMed ID: 31407969
[TBL] [Abstract][Full Text] [Related]
13. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
14. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
Shahait M; Abu-Hijlih R; Farkouh A; Obeidat S; Salah S; Abdlkadir AS; Al-Ibraheem A
J Egypt Natl Canc Inst; 2023 Jul; 35(1):21. PubMed ID: 37455263
[TBL] [Abstract][Full Text] [Related]
16. Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?
Yang Z; Cheng J; Pan L; Hu S; Xu J; Zhang Y; Wang M; Zhang J; Ye D; Zhang Y
Ann Nucl Med; 2012 Aug; 26(7):571-7. PubMed ID: 22763630
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
19. [Value of dual-phase (18)F-FDG PET/CT in preoperative staging of bladder cancer].
Li H; Wu H; Wang Q; Han Y; Wang Q
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):500-3. PubMed ID: 24752096
[TBL] [Abstract][Full Text] [Related]
20. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
